JP2022532038A5 - - Google Patents

Info

Publication number
JP2022532038A5
JP2022532038A5 JP2021563262A JP2021563262A JP2022532038A5 JP 2022532038 A5 JP2022532038 A5 JP 2022532038A5 JP 2021563262 A JP2021563262 A JP 2021563262A JP 2021563262 A JP2021563262 A JP 2021563262A JP 2022532038 A5 JP2022532038 A5 JP 2022532038A5
Authority
JP
Japan
Prior art keywords
administering
combination
pharmaceutical compositions
therapeutic agent
cell proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021563262A
Other languages
English (en)
Japanese (ja)
Other versions
JP7650001B2 (ja
JP2022532038A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/061477 external-priority patent/WO2020216911A1/en
Publication of JP2022532038A publication Critical patent/JP2022532038A/ja
Publication of JP2022532038A5 publication Critical patent/JP2022532038A5/ja
Application granted granted Critical
Publication of JP7650001B2 publication Critical patent/JP7650001B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021563262A 2019-04-26 2020-04-24 ｍＲＮＡ製剤 Active JP7650001B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19171323 2019-04-26
EP19171323.9 2019-04-26
PCT/EP2020/061477 WO2020216911A1 (en) 2019-04-26 2020-04-24 Mrna formulation

Publications (3)

Publication Number Publication Date
JP2022532038A JP2022532038A (ja) 2022-07-13
JP2022532038A5 true JP2022532038A5 (enExample) 2023-04-24
JP7650001B2 JP7650001B2 (ja) 2025-03-24

Family

ID=66290283

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563262A Active JP7650001B2 (ja) 2019-04-26 2020-04-24 ｍＲＮＡ製剤

Country Status (12)

Country Link
US (1) US20220362360A1 (enExample)
EP (1) EP3958893A1 (enExample)
JP (1) JP7650001B2 (enExample)
KR (1) KR20220023340A (enExample)
CN (1) CN114096272B (enExample)
AU (1) AU2020263948B2 (enExample)
BR (1) BR112021021262A2 (enExample)
CA (1) CA3138011A1 (enExample)
IL (1) IL287560B2 (enExample)
MX (1) MX2021013018A (enExample)
SG (1) SG11202111720TA (enExample)
WO (1) WO2020216911A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7496623B2 (ja) * 2019-01-04 2024-06-07 イーザアールエヌーエー イムノセラピーズ エンヴェー ｍＲＮＡワクチン
US20220143161A1 (en) * 2019-03-13 2022-05-12 Etherna Immunotherapies Nv Mrna vaccine
CN119701015A (zh) * 2023-09-26 2025-03-28 深圳瑞吉生物科技有限公司 一种细胞因子mRNA组合药物及其应用
CN121873266A (zh) * 2026-03-18 2026-04-17 北京悦康科创医药科技股份有限公司 一种增强肿瘤疫苗免疫原性的嵌合多肽及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2201100E (pt) * 2007-09-14 2016-06-03 Univ Brussel Vrije Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação
US20130108663A1 (en) * 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
US9408909B2 (en) * 2007-09-14 2016-08-09 Vrije Universiteit Brussel Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
EP3173474A1 (en) * 2007-09-14 2017-05-31 Vrije Universiteit Brussel Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
WO2015071295A1 (en) 2013-11-12 2015-05-21 Vrije Universiteit Brussel Rna transcription vector and uses thereof
DK4276189T3 (da) * 2015-09-21 2026-05-26 Trilink Biotechnologies Llc Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
EP4596041A3 (en) Farnesoid x receptor agonists and uses thereof
JP2024109585A5 (enExample)
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
JP2017506624A5 (enExample)
JP2014530220A5 (enExample)
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
HK1222297A1 (zh) 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法
JP2012193216A5 (enExample)
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
JP2020536085A5 (enExample)
JP2016530291A5 (enExample)
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
MY207469A (en) Therapeutic compounds
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
JP2015537009A5 (enExample)
ZA201901370B (en) Formulations for oral administration of active agents
JP2013541583A5 (enExample)
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
CN110062628A (zh) 一种瑞卡帕布口服缓控释药物组合物及其用途